Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Financing ActivitiesCash from OperationsCash from OperationsChange in Accured ExpensesChange in Accured ExpensesChange in CashFree Cash FlowFree Cash FlowLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activities
Growth Metrics
Income Statement
Others
Ratios

Acro Biomedical (ACBM) Cash from Financing Activities (2017 - 2025)

Acro Biomedical has reported Cash from Financing Activities over the past 9 years, most recently at $25152.0 for Q4 2025.

  • Quarterly results put Cash from Financing Activities at $25152.0 for Q4 2025, up 144.43% from a year ago — trailing twelve months through Dec 2025 was $199924.0 (up 443.39% YoY), and the annual figure for FY2025 was $199924.0, up 443.39%.
  • Cash from Financing Activities for Q4 2025 was $25152.0 at Acro Biomedical, down from $58707.0 in the prior quarter.
  • Over the last five years, Cash from Financing Activities for ACBM hit a ceiling of $93759.0 in Q2 2025 and a floor of -$241635.0 in Q2 2021.
  • Median Cash from Financing Activities over the past 5 years was $6607.0 (2024), compared with a mean of $4128.0.
  • Biggest five-year swings in Cash from Financing Activities: tumbled 492.42% in 2021 and later surged 36811.11% in 2024.
  • Acro Biomedical's Cash from Financing Activities stood at $1091.0 in 2021, then plummeted by 78.74% to $232.0 in 2022, then surged by 4088.79% to $9718.0 in 2023, then rose by 5.89% to $10290.0 in 2024, then surged by 144.43% to $25152.0 in 2025.
  • The last three reported values for Cash from Financing Activities were $25152.0 (Q4 2025), $58707.0 (Q3 2025), and $93759.0 (Q2 2025) per Business Quant data.